Sign in to fuzzto save your conversations, follow your research and come back anytime.
IPCA Laboratories
SectorHealthcare
Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts. The company's facilities are approved by major drug regulatory authorities including the US FDA, UK MHRA, and others. Ipca has expanded through acquisitions and joint ventures, and has subsidiaries in various countries. The company focuses on research and development, and has recently acquired stakes in other pharmaceutical companies to strengthen its market position.
In the news
Ipca Q1 earnings beat estimates, stock upside limited
Ipca Labs surges 36% in one year, Nomura raises target to ₹2,060
Ipca Laboratories shares fall 2% to ₹1,701 amid mixed Q4 results
Ipca Laboratories drops 5th straight session, down 0.47%
Four Pharma Stocks in Focus: Licensing Deals & Fund Raises
Ipca Labs partners BRL for cancer, autoimmune drug development
Motilal Oswal's Jain recommends Siemens Energy, Ipca Lab stocks
HSBC highlights PB Fintech, Godrej Properties as 'forgotten gems' - up to 70% upside
Ipca Laboratories rises 2.87% for third straight session
Market Rotation: Energy, Pharma, and Infrastructure Win as Financials Lag
Prabhudas Lilladher recommends Ipca Laboratories buy at ₹1710 target
Ipca Labs Q3 profit jumps 31% to ₹326.3 crore on strong sales
Ipca Laboratories shares fall 2.11% amid mixed Q3 performance
Company insights, generated from the most recent coverage.
Volume of 136,633 shares is ~18% below the 1-month average of 257,338 — the decline lacks heavy institutional distribution, pointing more to thin liquidity/profit booking than a supply overhang.
Price broke below the 20-EMA (₹1,833), 50-SMA (₹1,850) and lower Bollinger Band (₹1,821), confirming the ₹1,911-1,913 shelf that had held as support is now lost.
No exchange filing, USFDA observation or broker action dated today — with Q2 FY27 results due in coming weeks, pre-results de-risking is the most plausible read of the move.